Thursday 16 October, 2025
Introduction: Mechanistic pharmacokinetic-pharmacodynamic (PKPD) modelling of longitudinal data is essential to understand changes in the physiological system due to therapeutic interventions….
Read morePoster: Drug/Disease Modelling - Oncology
Modelling of rituximab clearance reduction due to ibrutinib co-administration
Thursday 16 October, 2025
Objectives: Ibrutinib is an oral covalent inhibitor of Bruton’s tyrosine kinase indicated for the treatment of patients with B cell malignancies…
Read moreA comprehensive multi-scale in silico approach for predicting antibody-drug conjugate clinical efficacy across oncological indications
Thursday 16 October, 2025
Introduction: Antibody-drug conjugates (ADCs) represent a significant advancement in oncology therapeutics, offering targeted delivery of cytotoxic drugs to tumor cells….
Read moreA PB-QSP platform model for T cell-dependent bispecific antibodies
Thursday 16 October, 2025
Objectives: T-cell-dependent bispecific (TDB) antibody is a promising therapeutic modality in drug development for both hematologic and solid malignancies. The…
Read moreModeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
Thursday 16 October, 2025
Objectives: Trastuzumab is used to treat HER2-receptor positive breast cancer patients. Trastuzumab treatment is associated with cardiotoxicity, manifesting as a decline…
Read moreTherapeutic drug monitoring of endoxifen in ER-positive breast cancer patients: comparing data from clinical practice to model-based predictions.
Thursday 16 October, 2025
Objectives: Five years of adjuvant treatment with tamoxifen lowers estrogen receptor (ER)-positive breast cancer recurrence and mortality rates. Despite tamoxifen’s…
Read moreTumor Response Index (TRI): model-based prediction of tumor response and survival in metastatic colorectal cancer patients treated by mFOLFOX6 with bevacizumab
Thursday 16 October, 2025
Objectives: Tumor growth models have been developed for several chemotherapeutic and molecular targeted drugs and the predicted tumor growth index…
Read moreIntegration of early circulating tumour DNA (ctDNA) changes into tumour growth inhibition modelling.
Thursday 16 October, 2025
Introduction: Circulating tumour DNA (ctDNA) has been considered a surrogate marker to predict clinical response in several types of cancer and…
Read moreImpact of ABC gene single nucleotide polymorphisms in population pharmacokinetic of capecitabine and its metabolites 5′-deoxy-5-fluorouridine (5′-DFUR) 5-fluorouracil (5-FU) in patients with colorectal cancer
Thursday 16 October, 2025
Objectives: The aim of this study was (i) to assess the pharmacokinetics (PK) of capecitabine and its metabolites 5′-deoxy-5-fluorouridine (5′-DFUR)…
Read moreCustomizing the distribution of a masked, tumor-activated antibody with quantitative systems pharmacology
Thursday 16 October, 2025
Objective: Probody™ therapeutics (Pb-Txs) are masked monoclonal antibody (mAb) prodrugs designed to be preferentially activated by tumor-associated proteases. The peptide mask…
Read more